Applied Sciences

Journal Browser

► Journal Browser

Special Issue Information

Dear Colleagues,

Previously, the purpose of genetic testing was to corroborate diseases based on somatic mutations for inborn and metabolic diseases. Currently, PCR and chromosome analysis technologies are used in clinical testing, and genetic testing for hematopoietic tumors is performed not only for infectious diseases but also for malignant tumors. In pathological diagnosis, with the adoption of companion diagnostics for cancer, more information is required than can be obtained by PCR or Sanger sequencing for genetic abnormalities, and so next-generation sequencing has finally come into its place. Information on genetic aberrations based on disease origin can be obtained not only from large panels, but also from compact panel analysis of specific tumors, which is highly useful. I hope that the results will contribute to the improvement of genome testing technology by elucidating the genetic abnormalities of many cancers and their molecular mechanisms.

Dr. Tomomi Fujii
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

cancer
genomic diagnosis
molecular pathology
molecular biology
next-generation sequencers (NGS)
molecular target therapy
pathology

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

12 pages, 4154 KiB

Open AccessArticle

Overexpression of microRNA-345 Affects the Invasive Capacity of Pancreatic Ductal Adenocarcinoma Cell Lines by Suppressing MUC1 and TJP2 Expression

by Shigenobu Tatsumi, Tomomi Fujii, Aya Sugimoto, Yoko Sekita-Hatakeyama, Kohei Morita, Tomoko Uchiyama, Hiroe Itami, Maiko Takeda, Masaharu Yamazaki, Masayuki Sho and Chiho Ohbayashi

Appl. Sci. 2022, 12(11), 5351; https://doi.org/10.3390/app12115351 - 25 May 2022

Viewed by 1304

Abstract

The majority of pancreatic carcinomas are pancreatic ductal adenocarcinomas (PDAC), and the presence of non-invasive pancreatic intraepithelial neoplasia or intraductal papillary mucinous neoplasm, as an associated lesion, is considered important. These microscopic hyperplastic or grossly papillomatous lesions exhibit varying degrees of morphological atypia and may develop into invasive carcinomas. In this study, we investigated whether mucin-1 (MUC1) is involved in the progression of pancreatic carcinoma and examined the mechanisms by which microRNAs regulate MUC1 expression in vitro. In PDAC cell lines, suppression of MUC1 expression reduced cell proliferation and invasion; PDAC cell lines transfected with an miR-345 precursor suppressed the expression of MUC1, and reduced cell proliferation and invasion. Tight junction protein 2 (TJP2), a putative target of miR-345, is regulated by MUC1. The suppression of TJP2 expression reduced cell proliferation by inducing apoptosis. These results suggest that MUC1 and TJP2, the putative target molecules of miR-345, are critical in maintaining the invasive potential of pancreatic carcinoma cells, and regulating their expression may prevent the progression of non-invasive pancreatic intraductal lesions to invasive carcinomas. This study provides new insights for the development of novel molecular targeted therapies for pancreatic carcinomas. Full article

(This article belongs to the Special Issue Cancer Genomic Testing and Its Application to Molecular Pathology Diagnosis)

► Show Figures

Figure 1

Review

Jump to: Research

14 pages, 1921 KiB

Open AccessReview

Diagnostic Strategies for Urologic Cancer Using Expression Analysis of Various Oncogenic Surveillance Molecules—From Non-Coding Small RNAs to Cancer-Specific Proteins

by Tomomi Fujii, Tomoko Uchiyama, Maiko Takeda and Keiji Shimada

Appl. Sci. 2022, 12(15), 7390; https://doi.org/10.3390/app12157390 - 22 Jul 2022

Cited by 1 | Viewed by 1389

Abstract

Urinary-tract-related tumors are prone to simultaneous or heterogeneous multiple tumor development within the primary organ. Urologic tumors have a very high risk of recurrence in the long and short term. This may be related to the disruption of homeostasis on the genetic level, such as the induction of genetic mutations due to exposure to various carcinogenic factors and the disruption of cancer suppressor gene functions. It is essential to detect the cancer progression signals caused by genetic abnormalities and find treatment therapies. In this review, we discuss the usefulness of tumor-expressing clinical biomarkers for predicting cancer progression. Furthermore, we discuss various factors associated with disturbed intracellular signals and those targeted by microRNAs, which are representative of non-coding small RNAs. Full article

(This article belongs to the Special Issue Cancer Genomic Testing and Its Application to Molecular Pathology Diagnosis)

► Show Figures